Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.11 – $0.53
19% from low
Exchange
OTC Link
OS
Borrow rate
11.47%
Hard to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $144.4K | $97.8K | $9.0K | $132.8K | $410.9K | $846.2K | $2.3M |
| Cost of revenue | $440.2K | $1.1M | $47.6K | $6.3K | $32.1K | $680.9K | $311.1K | $1.3M |
| Gross profit | −$316.8K | −$944.1K | −$47.6K | $5.0K | $100.6K | −$270.0K | $535.1K | $1.0M |
| Gross margin | — | -653.7% | -48.6% | 56.0% | 75.8% | -65.7% | 63.2% | 44.1% |
| R&D | $437.3K | $643.4K | $468.3K | $4.5M | $5.5M | $5.2M | $6.6M | $5.0M |
| Operating income | −$5.6M | −$8.1M | −$10.0M | −$16.0M | −$16.1M | −$16.8M | −$18.7M | −$13.2M |
| EBITDA | −$115.2K | −$7.0M | −$10.0M | −$16.1M | −$11.7M | −$13.3M | −$12.6M | −$12.3M |
| Net income | $705.7K | −$10.5M | −$8.0M | −$16.8M | −$9.9M | −$18.9M | −$13.4M | −$13.1M |
| Net margin | — | -7269.5% | -8182.1% | -186245.3% | -7461.3% | -4610.0% | -1582.8% | -560.7% |
| EPS (diluted) | 0.05 | -0.81 | -0.29 | -0.38 | -0.16 | -0.29 | -0.19 | -0.16 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $6M | $-0.05 | $-0.06–$-0.04 | 1 |
| 2027 | $13M | $-0.04 | $-0.05–$-0.03 | 1 |
| 2028 | $30M | $0.02 | $0.02–$0.02 | 1 |
| 2029 | $53M | $0.07 | $0.05–$0.08 | 1 |
Forward consensus · source: Financial Modeling Prep
PERIMETER MED IMAGING AI
No one on the platform currently holds PYNKF.
No tracked institution reports a position in PYNKF as of their last filing.
No one on the platform has traded PYNKF yet.
| $33M |
| — |
| GTHPGuided Therapeutics, Inc. | $0.20 | -16.67% | $15M | — |
| IPDQFImpediMed Limited | $0.01 | -1.96% | $10M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 9.7× sales vs its 176.9× historical median P/S.
Fair value ≈ $3.53 · price $0.19 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$PYNKF has announced it has been selected to receive a contribution from the INOVAIT Pilot Fund to advance next-generation AI capabilities for its flagship product Claire, which received FDA approval earlier this year as the first AI-enabled device for use during breast cancer surgery. The project was one of 10 selected for funding in the latest round of the INOVAIT Pilot Fund call for applications. https://biotuesdays.com/2026/06/09/inovate-selects-perimeter-for-contribution-to-advance-ai-for-breast-cancer-surgery/
View on StockTwits ↗$PYNKF https://open.substack.com/pub/microcapopportunities/p/perimeter-medical-imaging-mco-thesis?r=flrqv&utm_campaign=post-expanded-share&utm_medium=web
View on StockTwits ↗$PYNKF wont be long before this company breaks out
View on StockTwits ↗$PYNKF’s FDA-approved Claire OCT+AI was recently highlighted during Chamath Palihapitiya’s appearance on The Joe Rogan Experience as part of a broader discussion on AI’s growing impact in healthcare. https://biotuesdays.com/2026/05/06/perimeters-fda-pma-approved-claire-octai-highlighted-on-the-joe-rogan-experience-podcast/
View on StockTwits ↗$PYNKF https://microcapopportunities.substack.com/p/perimeter-medical-imaging-ai-financing
View on StockTwits ↗$PYNKF Is this company going succeed or is the management going to drive it into the ground due to poor financial management?
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.